home All News open_in_new Full Article

European Commission Approves Tablet Formulation of BeOne Medicines’ BRUKINSA® for All Approved Indications

Tablets will advance treatment simplicity and convenience to meet patient needs across Europe SAN CARLOS, Calif. — BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the European Commission has approved a new film-coated tablet formulation of BRUKINSA® (zanubrutinib) for all approved indications. “Developed to meet the real-world […]


today 3 w. ago attach_file Society

attach_file Events
attach_file Other
attach_file Transport
attach_file Events
attach_file Politics
attach_file Other
attach_file Economics
attach_file Society
attach_file Politics
attach_file Sport
attach_file Economics
attach_file Other
attach_file Economics
attach_file Sport
attach_file Economics
attach_file Events
attach_file Other
attach_file Events
attach_file Society
attach_file Other


ID: 2916790545
Add Watch Country

arrow_drop_down